REVVITY, INC. is 11.1x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($11.30 B vs $1.02 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | EYPT | RVTY |
|---|---|---|
| Market cap | $1.02 B | $11.30 B |
| US-listed rank | #2627 | #873 |
| Revenue (latest FY) | $31.37M | $2.86B |
| Net income (latest FY) | -$231.96M | $241.20M |
| Net margin | -739.4% | 8.4% |
| P/E (trailing FY) | - | 46.8 |
| SEC filings | 1,308 | 1,736 |
REVVITY, INC. is 11.1x more valuable than EyePoint Pharmaceuticals, Inc. by market capitalization ($11.30 B vs $1.02 B).
In their latest fiscal years, EyePoint Pharmaceuticals, Inc. reported $31.37M in revenue while REVVITY, INC. reported $2.86B.
Full pages: EyePoint Pharmaceuticals, Inc. and REVVITY, INC., or browse the full rankings.